CordenPharma to provide excipients for Moderna's vaccine candidate

By The Science Advisory Board staff writers

May 28, 2020 -- A supplier of active pharmaceutical ingredients (API), CordenPharma, has inked a manufacturing agreement with Moderna. CordenPharma will manufacture large-scale volumes of Moderna's lipid excipient which will be used to manufacture Moderna's SARS-CoV-2 vaccine candidate, mRNA-1273.

Under the agreement, the companies are expanding their supply relationship to include CordenPharma locations in France and the U.S. The initial relationship began in 2016 between Moderna and CordenPharma Switzerland. Now, CordenPharma will immediately provide specialized lipid manufacturing to help Moderna meet increased demand in the coming months.

Moderna lays out plan for mRNA-1273 vaccine
Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute...
NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe,...
COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter